Key result
GLP-1 RA reduces cardiomyocyte lipid accumulation by ~0.6-fold, driven by decreased membranous VLDLR expression.
Why the study?
The mechanism by which GLP-1 receptor agonists protect against cardiometabolic diseases remains largely undetermined, including whether they modulate VLDL-induced lipid accumulation in cardiomyocytes.
Does the GLP-1 receptor agonist DMB reduce VLDL-induced intracellular lipid accumulation in murine atrial myocytes (HL-1)?
Does the GLP-1 receptor agonist DMB reduce VLDL-induced intracellular lipid accumulation in murine atrial myocytes (HL-1)?
In murine atrial myocytes, the GLP-1 receptor agonist DMB attenuates VLDL-induced intracellular lipid accumulation by reducing membranous VLDLR expression and altering LPL concentration, suggesting a novel cellular mechanism for GLP-1 RA cardioprotection.
Answers are grounded in this paper and cite their sources.
Supports preclinical exploration of GLP-1 RAs in cardiac lipid handling; leaves open clinical translation from in vitro data.
Background/Introduction Very low-density lipoprotein (VLDL), which carries lipids with the majority of triglycerides, is associated with cardiometabolic diseases. VLDL is internalised into cardiomyocytes via a specific receptor (VLDLR), which coordinates lipoprotein lipase (LPL) activity for the release of free fatty acids from VLDL. Excess VLDL induces lipid accumulation and results in lipotoxicity in cardiomyocytes. Glucagon-like peptide receptor agonist (GLP-1 RA), a medication used to treat type 2 diabetes mellitus, exhibits protective effects against cardiometabolic diseases. Mechanism remains largely undetermined. Purpose This study aimed to test the hypothesis that GLP-1 RA can modulate LDL activity and affect VLDL-induced lipid accumulation. Methods Isolated and purified 25 μg/mL VLDL was used to incubate murine atrial myocytes (HL-1) with or without 100 nM GLP-1 RA (6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline, DMB). BODIPY staining and immunofluorescence imaging were used to quantify intracellular lipid content. Membrane proteins were isolated separately, and western blotting was used to determine protein expression. LPL ELISA and activity assays were used to determine expression levels and activity. Results VLDL incubation significantly increased intracellular lipid accumulation in HL-1 cells by 2.148 ± 0.127 folds (P= 0.0024) compared to the control group, as shown by BODIPY staining. DMB, the GLP-1 RA in the treatment group, significantly attenuated VLDL-induced lipid accumulation by 0.550 ± 0.196 folds (P=0.0057) compared to the VLDL group. The membranous V-LDL receptor (V-LDLR) expression, which was enhanced with VLDL incubation, was decreased by 0.823 ±0.019 folds (P<0.0001) in the GLP-1 RA group. However, LPL activity, which was quantified and standardised in cell homogenate, did not change after 24 h of treatment. The time course of GLP-1 RA effect on LPL was further examined at 3, 6, 12, 24, and 48 h. The results showed that the effect of DMB on LPL concentration peaked at 24 h (0.379 ± 0.707 folds compared to the VLDL group, P<0.0001). Conclusions GLP-1 RA decreased VLDL-induced lipid accumulation in HL-1 cells by affecting VLDLR membranous expression and LPL concentration. These findings suggest a novel mechanism underlying the cardioprotective effects of GLP-1 RA.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2026) studied VLDL-induced lipid accumulation and lipotoxicity in cardiomyocytes. GLP-1 receptor agonist (6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline, DMB) vs. VLDL incubation without GLP-1 RA was evaluated on VLDL-induced intracellular lipid accumulation in HL-1 cells (0.550 ± 0.196-fold attenuation, p=0.0057). GLP-1 RA (DMB) attenuated VLDL-induced lipid accumulation in HL-1 cardiomyocytes by 0.550 ± 0.196 folds and decreased membranous VLDLR expression by 0.823 ± 0.019 folds.
Synapse has enriched 10 related papers. Consider them for comparative context: